AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
LDLC: heavier first-half losses
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
Clearlake Capital-Backed Unifrax Completes Acquisition of Lydall
Unifrax Announces Pricing of Notes Offering
Lydall Announces September 14, 2021 Special Meeting Results
Unifrax Obtains Committed Debt Financing from J.P. Morgan Led Consortium to Support Clearlake Capital-Backed Acquisition of Lydall, Inc.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Lydall, Inc. - LDL
LYDALL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lydall, Inc. - LDL
LDL Stock Price Increased 85.4%: Why It Happened
Shareholder Alert: Ademi LLP investigates whether Lydall, Inc. has obtained a Fair Price in its transaction with Unifrax
Lydall Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Lydall, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – LDL
Clearlake Capital-Backed Unifrax to Acquire Lydall, Inc. for $62.10 per share
Lydall, Inc. (LDL) CEO Sara Greenstein on Q1 2021 Results - Earnings Call Transcript
Recap: Lydall Q1 Earnings
Lydall Announces Stock Repurchase Program
Lydall: There's Still Plenty Of Room To Grow
Lydall CEO expects demand boom for filtration material used in N95 masks and indoor systems beyond the pandemic
Lydall's (LDL) CEO Sara Greenstein on Q4 2020 Results - Earnings Call Transcript
Lydall: Q4 Earnings Insights
Lydall Announces Fourth Quarter 2020 Results
Lydall's Earnings: A Preview
Lydall President & CEO Sara Greenstein Commends Biden Administration and ASTM International for New Face Covering Standards
Lydall to Report Fourth Quarter 2020 Results
Lydall's (LDL) CEO Sara Greenstein on Q3 2020 Results - Earnings Call Transcript
Lydall: Q3 Earnings Insights
Lydall Announces Third Quarter 2020 Results
Bank of America Corp DE Sells 30,619 Shares of Lydall, Inc. (NYSE:LDL)
Infection Control Market overview 2020, In-depth analysis with Impact of COVID-19, Types, Opportunities, Revenue and Forecast 2026
Infection Control Market Research Report with Detailed Analysis 2020 & Forecast to 2026
AQR Capital Management LLC Sells 26,393 Shares of Lydall, Inc. (NYSE:LDL)
Lydall Partners with XPRIZE, Empowering the Next Generation of Innovators in Developing Solutions to the COVID-19 Crisis
Global Non-woven - Industrial Membrane Market (2020 to 2025) - Proliferation of New Technologies Presents Opportunities - ResearchAndMarkets.com